ClinicalTrials.gg
RecruitingNCT07610395Cardinal COPDUpdated Oct 22, 2026

Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo as Treatment for RV in Participants With COPD

A Phase 2 interventional study of VPV 1000 mg and VPV 500 mg in Rhinovirus Infection, sponsored by Altesa Biosciences, Inc.. Recruiting at 46 sites in 2 countries. Open to participants aged 40 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Altesa Biosciences, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started May 2026; still recruiting 6 months later.
Updated Oct 22, 2026Site recruiting status changed2 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
180
Allocation
Randomized
Ages
40 Years to 85 Years
Sex
All
01

Study summary

Compare the safety and efficacy of two different oral vapendavir doses with placebo in order to determine the appropriate dose of vapendavir to reduce the severity and/or duration of respiratory symptoms associated with RV infections in patients with COPD.

02

Conditions studied

  • Rhinovirus Infection
03

In context

Lead sponsor

Altesa Biosciences, Inc. is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
40 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Sign for study participation and medical records release (if needed).

Male or female age ≥40 years and ≤85 years at the time of signing the informed consent at Screening.

If sexually active and/or of (both females and males), must agree to use a highly effective form of at the time of randomization until 30 days (females) or 90 days (males) after the last dose. Female participants may not use hormonal birth control as a sole method. Participants will be asked to commit to this criterion at screening even though it does not need to be implemented until treatment is received. See Section 11.2 below.

Confirmed diagnosis of , defined as chronic cough, sputum production, and/or dyspnea with airflow obstruction which is not fully reversible (that is, post bronchodilator /FVC ratio \<0.70 and post bronchodilator FEV1 ≥20% and \<80% of predicted normal value).

History of AECOPD with at least 1 documented AECOPD within 1 year of Screening.

  • AECOPD is defined as an event characterized by dyspnea and/or cough and increased sputum purulence/change in sputum color that worsens over several days, and requires at least one of the following for at least 2 days:
  • Increase frequency or dose of beta agonist(s), oxygen, breathing treatments or chronic COPD medications (Mild Exacerbation)
  • Use of oral or systemic (Moderate Exacerbation), or
  • Use of Antibiotics (Moderate Exacerbation), or
  • Emergency room visit or hospitalization (Severe Exacerbation). CAT score ≥10 at screening. Able to comply with all study requirements, including the use of a mobile application to complete daily PROs, perform nasal swabs at home, and able to assess when they have cold symptoms.

Interacts with people at least twice a week without a mask (e.g., grocery shopping, dinner with grandchildren, eating at a restaurant, going to the movies, etc.) or are living in a multigenerational home.

Inclusion criteria to be assessed only at Randomization:

If on stable COPD maintenance therapy this should be stable for at least 2 months prior to randomization. Changes allowed with Sponsor approval (i.e., change within same class due to financial considerations and clinically stable).

Clinically stable with no other exacerbations or respiratory infections (viral or bacterial) within 2 months prior to randomization.

The presence of RV (without a co-infection) at the time of randomization based on an approved molecular diagnostic test.

To be randomized, participants must have at least 3 E-RS scores completed within the previous 35 days to establish a PSB.

Exclusion criteria

Exclusion

Pregnant or nursing or expected to become pregnant during the study period. Experiencing a current/active or prior exacerbation within 2 months of the Screening Visit (these participants should be rescreened after the exacerbation has been resolved for two months).

Participants with other primary causes of chronic airflow limitation:

- Including but not limited to: asthma alone ( with asthmatic features is acceptable), CF, bronchiolitis obliterans, fibrosis such as TB, IPF, non-CF bronchiectasis with multi-lobe involvement or other major respiratory diagnosis (e.g., allergic bronchopulmonary aspergillosis), etc.

Any disorder, for example, cardiovascular, gastrointestinal, hepatic, renal, neurological, musculoskeletal, infectious, endocrine, metabolic, hematological, psychiatric impairment that is not medically stable, or other major physical impairment that is not considered by the investigator medically stable/controlled.

Participants with are excluded. Participants on a stable treatment for can be permitted with permission from the medical monitor. Participants with should be treated and confirmed HCV RNA negative prior to enrollment. (Testing performed at the Screening Visit).

In the Investigator's opinion, the participant has any laboratory abnormality including an abnormality that indicates clinically significant hematologic, hepatobiliary, or renal disease.

Presence of clinically significant out-of-range cardiac interval on the screening including a > 450 msec (men) and a QTcF > 460 msec (women).

Medications or other non-medicinal products that could be impacted by , CYP2C8, or CYP2C19 induction and have serious complications for the participant within the treatment period.

Medications that are potent CYP2C8, CYP3A4 or CYP2C19 inducers that would reduce exposures of VPV.

Medications that are potent CYP2C8, CYP3A4, or CYP2C19 inhibitors that would increase exposures of VPV.

Medications that are substrates of MATE1, OAT3, P-gp, and BCRP for which elevated concentrations are associated with serious and/or life-threatening reactions.

Use of either of the following treatments:

  • Chronic oral/systemic >10 mg per day (inhaled corticosteroids are permitted).
  • Continuous oxygen via nasal cannula of >2 L/min at the time of Screening or during the Asymptomatic Phase. (Participants on continuous oxygen may have the rate increased during physical exercise/ exertion or to cover any situationally induced decompensation, so long as the participant will resume a continuous rate of ≤2 L/min thereafter).

Participation in another drug study within 5 half-lives prior to Screening and during the study is prohibited. This includes approved drugs being evaluated for a new indication. Observational studies are permitted.

Participants who have taken VPV in another clinical trial.

Exclusion criteria to be assessed only at Randomization:

It is already determined, based on the Investigator's clinical judgement, that the participant will likely need antibiotics and/or oral steroids at the Day 1 Randomization Visit.

On or within 7 days prior to randomization, there is another active diagnosed infection with viral or bacterial pathogens (i.e., urinary tract infection, cellulitis, etc.) that requires treatment.

Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
180 participants (estimated)

Study arms

  • Experimental
    Dosing Group 1 VPV 1000 mg

    The first dose of 1,000 mg VPV will be taken at the study site with food once the Day 1 visit is completed. The second dose of 1,000 mg VPV will be taken at home the following morning with food. The subsequent 1,000 mg doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses.

    Drug: VPV 1000 mg

  • Experimental
    Dosing Group 2 VPV 500 mg

    The first dose of 1,000 mg VPV will be taken at the study site with food once the Day 1 visit is completed. The second dose of 500 mg VPV will be taken at home the following morning with food. The subsequent 500 mg doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses.

    Drug: VPV 1000 mg · Drug: VPV 500 mg

  • Placebo comparator
    Dosing Group 3 Placebo

    The first dose of placebo will be taken at the study site with food once the Day 1 visit is completed. The second dose of placebo will be taken at home the following morning with food. The subsequent placebo doses will be taken every 24 hours with food from the time of the second dose for a total of 7 doses

    Other: Placebo

Interventions

  • Vapendavir 1000 mg

    Also known as: Vapendavir

  • DrugVPV 500 mg

    Vapendavir 500 mg

    Also known as: Vapendaivr

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Evaluating Respiratory Symptoms (E-RS)

    11-item E RS collected as part of the 14-item EXAcerbations of Chronic pulmonary disease Tool (EXACT PRO®) scale, with data from the additional 3 items from the EXACT PRO scale used for exploratory purposes only. The PSB will be calculated as the mean of the E-RS scores collected in the -35 to -6 days prior to RV symptom onset. If the E-RS score has not returned to PSB at the time of Day 28 Visit, the participant will complete the E-RS daily until Day 42. The questions are asked about how the participant feels today and will be collected at night.

    Time frame: Baseline Period/Asymptomatic Phase: Daily for 12 weeks Treatment/Follow-Up Periods: Daily for up to 42 days

Secondary outcomes

  1. Patient Global Impression of Severity (PGIS)

    The PGIS is one question, 'Please rate the overall severity of your respiratory symptoms today? (none, mild, moderate, severe, very severe).'

    Time frame: Baseline Period/Asymptomatic Phase: Daily for 12 weeks Treatment/Follow-Up Periods: Daily for up to 42 days

  2. Wisconsin Upper Respiratory Symptom Survey - 11

    The questions are asked about how the participant feels today or within the last 24 hours. The questionnaire will be completed at night.

    Time frame: Treatment/Follow-up Periods: Daily for 28 days

  3. Change from Baseline in Respiratory System Resistance at 5 Hz (R5) Measured by Oscillometry

    Respiratory system resistance at an oscillation frequency of 5 Hz, measured by oscillometry during unforced tidal breathing. R5 reflects total respiratory system resistance and is a measure of overall airway caliber. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.

    Time frame: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42

  4. Change from Baseline in Respiratory System Resistance at 20 Hz (R20) Measured by Oscillometry

    Respiratory system resistance at an oscillation frequency of 20 Hz, measured by oscillometry during unforced tidal breathing. R20 predominantly reflects large/central airway resistance, as higher-frequency oscillations do not penetrate the peripheral airways. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.

    Time frame: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42

  5. Change from Baseline in Frequency Dependence of Resistance (R5-R20) Measured by Oscillometry

    The difference between respiratory system resistance measured at 5 Hz and at 20 Hz (R5 minus R20), measured by oscillometry during unforced tidal breathing. R5-R20 is interpreted as an index of small airway dysfunction, with elevated values indicating heterogeneity of peripheral airway resistance. Values are calculated from the mean of at least three technically acceptable measurements at each frequency, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.

    Time frame: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42

  6. Change from Baseline in Respiratory System Reactance at 5 Hz (X5) Measured by Oscillometry

    Respiratory system reactance at an oscillation frequency of 5 Hz, measured by oscillometry during unforced tidal breathing. X5 represents the elastic and inertive properties of the respiratory system at low frequency and becomes more negative with increased peripheral airway obstruction or reduced lung compliance. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O·s/L.

    Time frame: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42

  7. Change from Baseline in Area Under the Reactance Curve (AX) Measured by Oscillometry

    The integrated area of the reactance curve from 5 Hz to the resonant frequency, measured by oscillometry during unforced tidal breathing. AX reflects the total elastic and inertive load of the respiratory system and is a sensitive composite index of peripheral airway dysfunction. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: cmH₂O/L.

    Time frame: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42

  8. Change from Baseline in Resonant Frequency (Fres) Measured by Oscillometry

    The oscillation frequency at which respiratory system reactance equals zero, measured by oscillometry during unforced tidal breathing. Fres represents the frequency at which the inertive and elastic forces of the respiratory system are equal in magnitude and opposite in direction; it shifts to higher frequencies with peripheral airway obstruction. Values are reported as the mean of at least three technically acceptable measurements, performed according to the 2020 European Respiratory Society / American Thoracic Society technical standards for respiratory oscillometry. Unit of measure: Hz.

    Time frame: Screening Visit, Day 1, Day 3, Day 7, Day 14, Day 28, Day 42

  9. Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) - Absolute Value

    Forced expiratory volume in the first second of a maximal forced expiration following a full inspiration, measured by spirometry. FEV1 is a primary index of airflow obstruction. Values are reported as the highest acceptable value from at least three acceptable and two repeatable maneuvers, performed according to the 2019 European Respiratory Society / American Thoracic Society standards for spirometry. Unit of measure: liters.

    Time frame: Screening Visit, and Days 7, 14, 28 and 42

  10. Change from Baseline in Forced Expiratory Volume in 1 Second (FEV1) - Percent Predicted

    Forced expiratory volume in the first second expressed as a percentage of the predicted value for the participant's age, sex, height, and ethnicity using the Global Lung Function Initiative (GLI-2012) reference equations. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: percent of predicted (%).

    Time frame: Screening Visit, Day 7, Day 14, Day 28, Day 42

  11. Change from Baseline in Forced Vital Capacity (FVC) - Absolute Value

    Forced vital capacity, defined as the maximum volume of air exhaled with maximally forced effort from a position of maximal inspiration, measured by spirometry. Values are reported as the highest acceptable value from at least three acceptable and two repeatable maneuvers, performed according to the 2019 European Respiratory Society / American Thoracic Society standards for spirometry. Unit of measure: liters.

    Time frame: Screening Visit, Day 7, Day 14, Day 28, Day 42

  12. Change from Baseline in Forced Vital Capacity (FVC) - Percent Predicted

    Forced vital capacity expressed as a percentage of the predicted value for the participant's age, sex, height, and ethnicity using the Global Lung Function Initiative (GLI-2012) reference equations. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: percent of predicted (%).

    Time frame: Screening Visit, Day 7, Day 14, Day 28, Day 42

  13. Change from Baseline in FEV1/FVC Ratio

    The ratio of forced expiratory volume in 1 second (FEV1) to forced vital capacity (FVC), calculated from the highest acceptable FEV1 and FVC obtained during the same testing session. The FEV1/FVC ratio is the principal spirometric criterion used to identify airflow obstruction. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: ratio.

    Time frame: Screening Visit, Day 7, Day 14, Day 28, Day 42

  14. Change from Baseline in Peak Expiratory Flow (PEF) - Absolute Value

    Peak expiratory flow, defined as the highest flow achieved during a maximally forced expiration starting from a position of maximal inspiration, measured by spirometry. Values are reported as the highest acceptable value from at least three acceptable and two repeatable maneuvers, performed according to the 2019 European Respiratory Society / American Thoracic Society standards for spirometry. Unit of measure: liters per minute (L/min).

    Time frame: Screening Visit, Day 7, Day 14, Day 28, Day 42

  15. Change from Baseline in Peak Expiratory Flow (PEF) - Percent Predicted

    Peak expiratory flow expressed as a percentage of the predicted value for the participant's age, sex, height, and ethnicity using the Global Lung Function Initiative (GLI-2012) reference equations. Measured by spirometry according to the 2019 European Respiratory Society / American Thoracic Society standards. Unit of measure: percent of predicted (%).

    Time frame: Screening Visit, Day 7, Day 14, Day 28, Day 42

07

Study locations

38 of 46 sites recruiting
  • Velocity Clinical Research - Mobile
    Mobile, Alabama 36608, United States
    Recruiting
    • Velocity Clinical Research - Mobile · Contact
  • AMR Clinical - Tempe
    Tempe, Arizona 85281, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • 310 Clinical Research, LLC
    Inglewood, California 90301, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • NewportNativeMD, Inc.
    Newport Beach, California 92663, United States
    Recruiting
    • NewportNativeMD, Inc. · Contact
  • Apex Clinical Research
    San Diego, California 92120, United States
    Recruiting
    • Apex Clinical Research · Contact
  • Synergy Health
    Bradenton, Florida 34209, United States
    Recruiting
    • Synergy Health · Contact
  • VM Clintrials
    Miami Lakes, Florida 33014, United States
    Recruiting
    • VM Clintrials · Contact
  • Medquest Translational Sciences
    Miami Lakes, Florida 33016, United States
    Recruiting
    • Medquest Translational Sciences · Contact
  • Metropolitan Clinical Research Center
    Tamarac, Florida 33321, United States
    Recruiting
    • Metropolitan Clinical Research Center · Contact
  • Covenant Critical Pulmonary Care
    East Point, Georgia 30344, United States
    Recruiting
    • Covenant Critical Pulmonary Care · Contact
  • Accelerated Clinical Trials
    Snellville, Georgia 30078, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Bioluminux Clinical Research Illinois
    Naperville, Illinois 60540, United States
    Recruiting
    • Bioluminux Clinical Research Illinois · Contact
  • Velocity Clinical Research - Valparaiso
    Valparaiso, Indiana 46383, United States
    Recruiting
    • Velocity Clinical Research - Valparaiso · Contact
  • AMR Clinical - Lexington
    Lexington, Kentucky 40509, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Patient First Clinical Trials (PFCTRIALS)
    Lutherville, Maryland 21093, United States
    Recruiting
    • Patient First Clinical Trials (PFCTRIALS) · Contact
  • Verexa Health
    Dearborn, Michigan 48126, United States
    Recruiting
    • Verexa Health · Contact
  • Oakland Medical Research
    Troy, Michigan 48085, United States
    Recruiting
    • Oakland Medical Research · Contact
  • AMR Clinical - Las Vegas
    Las Vegas, Nevada 89119, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Bioluminux Clinical Research New Jersey
    Hamilton, New Jersey 08690, United States
    Recruiting
    • Bioluminux Clinical Research New Jersey · Contact
  • Velocity Clinical Research - Binghamton
    Binghamton, New York 13905, United States
    Recruiting
    • Velocity Clinical Research - Binghamton · Contact
  • Brooklyn Clinical Research
    Brooklyn, New York 11226, United States
    Recruiting
    • Brooklyn Clinical Research · Contact
  • CRC Kings Mountain
    Kings Mountain, North Carolina 28086, United States
    Recruiting
    • CRC Kings Mountain · Contact
  • Remington-Davis, Inc.
    Columbus, Ohio 43215, United States
    Recruiting
    • Remington-Davis, Inc. · Contact
  • Hometown Urgent Care - Milford
    Milford, Ohio 45150, United States
    Recruiting
    • Hometown Urgent Care - Milford · Contact
  • Tekton Research
    Edmond, Oklahoma 73013, United States
    Recruiting
    • Tekton Research · Contact
  • Velocity Clinical Research - Medford
    Medford, Oregon 97504, United States
    Recruiting
    • Velocity Clinical Research - Medford · Contact
  • Clinical Research Associates of Central PA, LLC
    DuBois, Pennsylvania 15801, United States
    Recruiting
    • Clinical Research Associates of Central PA, LLC l · Contact
  • Preferred Primary Care Physicians - St. Clair
    Pittsburgh, Pennsylvania 15423, United States
    Recruiting
    • Preferred Primary Care Physicians - St. Clair · Contact
  • Guthrie Medical Group, PC
    Sayre, Pennsylvania 18840, United States
    Recruiting
    • Guthrie Medical Group, PC · Contact
  • Velocity Clinical Research - Anderson
    Anderson, South Carolina 29621, United States
    Recruiting
    • Velocity Clinical Research - Anderson · Contact
  • Clinical Research of Rock Hill
    Rock Hill, South Carolina 29732, United States
    Recruiting
    • Clinical Research of Rock Hill · Contact
  • Velocity Clinical Research - Spartanburg
    Spartanburg, South Carolina 29303, United States
    Recruiting
    • Velocity Clinical Research - Spartanburg · Contact
  • Velocity Clinical Research - Union
    Union, South Carolina 29379, United States
    Recruiting
    • Velocity Clinical Research - Union · Contact
  • Zenos Clinical Research, LLC
    Dallas, Texas 75230, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Activian Clinical Research - Kingwood
    Kingwood, Texas 77339, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Epic Clinical Research, LLC
    Lewisville, Texas 75057, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Activian Clinical Research - Tomball
    Tomball, Texas 77375, United States
    Recruiting
    • Activian Clinical Research - Tomball · Contact
  • FutureMeds Liverpool
    Bromborough, CH62 6EE, United Kingdom
    Recruiting
    • FutureMeds Liverpool · Contact
  • FutureMeds Glasgow
    Glasgow, G20 7BE, United Kingdom
    Recruiting
    • FutureMeds Glasgow · Contact
  • Imperial Clinical Respiratory Research Unit
    London, NW1 0NH, United Kingdom
    Recruiting
    • Imperial Clinical Respiratory Research Unit · Contact
  • FutureMeds London
    London, NW10 2PB, United Kingdom
    Recruiting
    • FutureMeds London · Contact
  • Clinicalysis
    London, RM1 1BH, United Kingdom
    Recruiting
    • CLINICALYSIS · Contact
  • ProMed Innovations Clinical Research
    London, SE6 4LF, United Kingdom
    Recruiting
    • ProMed Innovations Clinical Research · Contact
  • Imperial College Healthcare NHS Trust
    London, W12 0HS, United Kingdom
    Recruiting
    • Imperial College Healthcare NHS Trust · Contact
  • Bioluminux Clinical Research Milton Keynes
    Milton Keynes, MK15 0DU, United Kingdom
    Recruiting
    • Bioluminux Clinical Research Milton Keynes · Contact
  • Bioluminux Clinical Research Wolverhampton
    Wolverhampton, WV9 5HB, United Kingdom
    Recruiting
    • Bioluminux Clinical Research Wolverhampton · Contact
08

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2026 (actual). Primary completion is estimated for Nov 2027, 18 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
May 12, 2026
First posted
May 28, 2026
StartActual
May 1, 2026
Primary completionEst.
Nov 15, 2027
CompletionEst.
Nov 15, 2027
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites added. 3 sites changed recruiting status (3 now active, not recruiting)
Show 3 sites
  • AMR Clinical - Lexington · Lexington, United StatesRecruiting→Active, not recruiting
  • AMR Clinical - Tempe · Tempe, United StatesRecruiting→Active, not recruiting
  • AMR Clinical - Las Vegas · Las Vegas, United StatesRecruiting→Active, not recruiting
Show 2 added (2 United Kingdom)
  • Imperial Clinical Respiratory Research Unit · London, United Kingdom
  • Imperial College Healthcare NHS Trust · London, United Kingdom
across 2 updates, Oct 16, 2026 – Oct 22, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • AMR Clinical - Lexington · Lexington, United StatesContact removed (no phone or email listed)
  • AMR Clinical - Tempe · Tempe, United StatesContact removed (no phone or email listed)
  • AMR Clinical - Las Vegas · Las Vegas, United StatesContact removed (no phone or email listed)
across 2 updates, Oct 16, 2026 – Oct 22, 2026
Show all 2 updates
  1. Oct 22, 2026
    2 sites changed recruiting status (2 now active, not recruiting)
    Show 2 sites
    • AMR Clinical - Tempe · Tempe, United StatesRecruiting→Active, not recruiting
    • AMR Clinical - Las Vegas · Las Vegas, United StatesRecruiting→Active, not recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • AMR Clinical - Tempe · Tempe, United StatesContact removed (no phone or email listed)
    • AMR Clinical - Las Vegas · Las Vegas, United StatesContact removed (no phone or email listed)
  2. Oct 16, 2026
    2 sites added. AMR Clinical - Lexington is now Active, not recruiting
    Show 2 added (2 United Kingdom)
    • Imperial Clinical Respiratory Research Unit · London, United Kingdom
    • Imperial College Healthcare NHS Trust · London, United Kingdom
    Site contacts Changed at 1 site. See the sites
    Show the site
    • AMR Clinical - Lexington · Lexington, United StatesContact removed (no phone or email listed)
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07610395
Lead sponsor
Altesa Biosciences, Inc.
Responsible party
Sponsor
First posted
May 28, 2026
Start date
May 1, 2026
Primary completion
Nov 15, 2027 (estimated)
Completion
Nov 15, 2027 (estimated)
Last update
Oct 22, 2026

Study contacts

Karen Fusaro
Contact
kfusaro@altesa.com
610-242-0903

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vapendavir

Start the discussion